Published 07/24/2024 9:24:01 a.m.

Union Budget 2024: AstraZeneca set to gain from customs duty exemption on key cancer drugs in full Budget

Summary by Business Today

These drugs --Trastuzumab Deruxtecan, Osimertinib, and Durvalumab -- are manufactured by AstraZeneca plc, a British-Swedish multinational pharmaceutical and biotechnology company, and supplied in India by its subsidiary, AstraZeneca Pharma India Limited, based in Bengaluru.

0 Articles

All

Left

Center

Right

Business Today

Union Budget 2024: AstraZeneca set to gain from customs duty exemption on key cancer drugs in full Budget

07/24/2024 9:24:01 a.m.·India

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources0

Leaning Left0Leaning Right0Center0Last Updated07/25/2024 3:17:28 a.m.Bias Distribution

No sources with tracked biases.

Bias Distribution

There is no tracked Bias information for the sources covering this story.

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Union Budget 2024: AstraZeneca set to gain from customs duty exemption on key cancer drugs in full Budget

0 Articles

0 Articles

Union Budget 2024: AstraZeneca set to gain from customs duty exemption on key cancer drugs in full Budget

Union Budget 2024: AstraZeneca set to gain from customs duty exemption on key cancer drugs in full Budget

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics